Ralph Weichselbaum to MicroRNAs
This is a "connection" page, showing publications Ralph Weichselbaum has written about MicroRNAs.
Connection Strength
2.231
-
In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases. Mol Ther. 2017 07 05; 25(7):1588-1595.
Score: 0.356
-
microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
Score: 0.307
-
14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
Score: 0.307
-
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014 Aug; 31(6):735-48.
Score: 0.293
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.263
-
MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650.
Score: 0.245
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
Score: 0.138
-
Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomaterials. 2019 07; 210:94-104.
Score: 0.102
-
DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662.
Score: 0.100
-
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol. 2010 Apr 01; 6(4):e1000730.
Score: 0.055
-
Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Clin Cancer Res. 2019 03 15; 25(6):1795-1808.
Score: 0.025
-
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
Score: 0.021
-
Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
Score: 0.021